Overall study design~This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.~Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first.~Interim analysis will be permitted as described in the statistical section 8.~The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.~Number of subjects~• Up to 36 patients in track 2, and 19 patients in track 3 as described in the statistical section 8.~Overall study duration~The study begins when the first subject (this will likely be a donor) signs the informed consent. The study will end once the last enrolled subject completes the study (likely a recipient).~The expected duration of the study is approximately 12 months.
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.~Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first.~Interim analysis will be permitted as described in the statistical section 8.~The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.